Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway - 22/03/24
, Na Ma c, ⁎ , Li Xu d, ⁎ Abstract |
Dasatinib-related resistance frequently occurs and may lead to the failure of chemotherapy; thus, dose interruptions are necessary. Cannabidiol (CBD) has potential for integration with orthodox cancer care. In this study, we explored the combination effect of CBD and dasatinib on A549 cells. CBD in combination with dasatinib could induce significant synergistic apoptosis in vitro (ZIP > 10) and in vivo. The combination of CBD and low-dose dasatinib exhibited antiproliferative and proapoptotic effects through up-regulation of caspase-3 and Bax, and down-regulation of Bcl-2 in A549 cells. The xenograft mouse model suggested that the combination was more efficient and safer. In short, CBD and low-dose dasatinib exhibited a synergistic effect on anticancer by targeting the SRC/PI3K/AKT signaling pathway, suggesting a potential therapeutic option for the treatment of lung cancer.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Low-dose dasatinib plus CBD showed a synergistic effect in lung cells. |
• | Dasatinib combined with CBD alleviated its side effects. |
• | The synergistic effect acts by SRC/PI3K/AKT and Bax/Bcl-2/caspase-3 athways. |
Keywords : Lung cancer, Dasatinib, Cannabidiol, Synergistic effect, Apoptosis, SRC/PI3K/AKT pathway
Plan
Vol 173
Article 116445- avril 2024 Retour au numéro
Article précédent
- α-synuclein regulates Cyclin D1 to promote abnormal initiation of the cell cycle and induce apoptosis in dopamine neurons
- Xiaokang Jia, Qiliang Chen, Ciyu Yao, Tetsuya Asakawa, Yuanyuan Zhang
- Nrf-2-dependent antioxidant and anti-inflammatory effects underlie the protective effect of esculeoside A against retinal damage in streptozotocin-induced diabetic rats
- Nasser A. Alsabaani, Kawther Amawi, Samy M. Eleawa, Wisam Nabeel Ibrahim, Walid Aldhaban, Ahmad Mohammad Alaraj, Badr Alkhalaf, Waqas Sami, Hisham Alshaikhli, Mahmoud A. Alkhateeb
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?